Iovance Biotherapeutics Inc. (NASDAQ:IOVA) currently has a daily average trading volume of 4.09M but it saw 2458803 shares traded on Thursday. With a market cap of 1.55B USD, stock’s current market price of $6.62 came falling about -2.93 while comparing to the previous closing price of $6.82. In past 52 weeks, the stock remained buoying in the range of price level as high as $18.73 and as low as $5.42. In the recent trading on the day, stock has struck highest price mark of $6.85 while lowest mark touched by it was $6.46.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of Iovance Biotherapeutics Inc. (IOVA) gives us an average price of $6.98, while its current price level is -64.66% below from 52-week high level whereas it is 22.14% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $7.08 while that of 200 days or SMA-200 reads an average of $8.92. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.07% during that period while stretching the period over a month that decreases to 5.68%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 43.92 which implies that the stock is in neutral territory.
The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $6.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $40.00. Average price target assigned by them is $22.25 which highlights an upside potential of 70.25% for the stock over that period. And to attain the median price target of $21.00 assigned by those analysts, stock has to add about 68.48% of value to its current levels.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Piper Sandler which upgraded the stock as “Overweight” in its note to investors issued on January 27, 2023, recommending a price target of between $11 and $14 for it. Goldman downgraded its recommendation for the stock as a “Neutral” from “Buy” on December 09, 2022 while assigning a price target range of $20-$6.
Over the week, IOVA’s stock price is moving 2.00% up while it is -9.81% when we observe its performance for the past one month. Year-to-date it is 3.60% up and over the past year, the stock is showing a downside performance of -47.08%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of -$0.63 beat the consensus estimate of -$0.64 for the same. For IOVA, analysts are forecasting an EPS-growth rate of -11.70% for current year and estimate for EPS growth in next year is -4.80%.
Currently, Iovance Biotherapeutics Inc.’s total number of outstanding shares is 164.82M with 0.52% of that held by the insiders while 120.45% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -82.60%. Stock’s beta reads 0.25. Stock has a price to book (P/B) ratio of 2.18. Its return on asset (ROA) is -62.80% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by -0.88% in the Iovance Biotherapeutics Inc. (IOVA) decreasing its stake to 6.21% with control over 87240.0 shares in the company. In the most recent quarter, Vanguard Small Cap Index Fund came rising its stake by 0.55% in the company and now holds 3.88 million or 2.46% of the company’s stake having worth of about 28.32 million.
